A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Phase 2 Active, not recruiting NCT03246347

Condition	Prostate Cancer, Prostate Adenocarcinoma
Phase	Phase 2
Sponsor	Wake Forest University Health Sciences
Status	Active, not recruiting
Enrollment	40 participants
Interventions	ADT+Docetaxel+Enzalutamide
Start date	Aug 23, 2017
Completion date	Sep 1, 2022
Results posted	Sep 22, 2023

Summary

This is a study with the combination of androgen deprivation therapy (ADT) and docetaxel with the addition of enzalutamide in the treatment of subjects with metastatic prostate cancer. The purpose of this study is to assess if ADT + docetaxel + enzalutamide is well tolerated and demonstrates improved efficacy compared to ADT + docetaxel.

52-week PSA Complete Response (CR) Rate

52 weeks · Participants

Single Arm	22 Participants

p-value	<0.001
Proportion	.6111 (95% CI .4346–.7686)

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate — Aragon Pharmaceuticals, Inc.
Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery — Wake Forest University Health Sciences
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced P — National Cancer Institute (NCI)
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castr — National Cancer Institute (NCI)
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abirate — Janssen Research & Development, LLC
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Ola — National Cancer Institute (NCI)

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский